Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults
NCT05383560Phase 2Completed
- Sponsor
- Sheba Medical Center
- Start
- Sep 2022
- Primary completion
- Jan 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of elasomeran + imelasomeran, elasomeran + davesomeran in coronavirus disease 2019 (COVID-19), sponsored by Sheba Medical Center. Started Sep 2022; status: completed.
02
Drugs
elasomeran + imelasomeranelasomeran + davesomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05383560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05383560.